Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Orphanet J Rare Dis. 2019 May 23;14(1):114. doi: 10.1186/s13023-019-1070-0.
Current diagnostic tests for hereditary spherocytosis (HS) focus on the detection of hemolysis or indirectly assessing defects of membrane protein, whereas direct methods to detect protein defects are complicated and difficult to implement. In the present study, we investigated the patterns of genetic variation associated with HS among patients clinically diagnosed with HS.
Multi-gene targeted sequencing of 43 genes (17 RBC membrane protein-encoding genes, 20 RBC enzyme-encoding genes, and six additional genes for the differential diagnosis) was performed using the Illumina HiSeq platform.
Among 59 patients with HS, 50 (84.7%) had one or more significant variants in a RBC membrane protein-encoding genes. A total of 54 significant variants including 46 novel mutations were detected in six RBC membrane protein-encoding genes, with the highest number of variants found in SPTB (n = 28), and followed by ANK1 (n = 19), SLC4A1 (n = 3), SPTA1 (n = 2), EPB41 (n = 1), and EPB42 (n = 1). Concurrent mutations of genes encoding RBC enzymes (ALDOB, GAPDH, and GSR) were detected in three patients. UGT1A1 mutations were present in 24 patients (40.7%). Positive rate of osmotic fragility test was 86.8% among patients harboring HS-related gene mutations.
This constitutes the first large-scaled genetic study of Korean patients with HS. We demonstrated that multi-gene target sequencing is sensitive and feasible that can be used as a powerful tool for diagnosing HS. Considering the discrepancies of clinical and molecular diagnoses of HS, our findings suggest that molecular genetic analysis is required for accurate diagnosis of HS.
目前遗传性球形红细胞增多症(HS)的诊断检测侧重于溶血的检测或间接评估膜蛋白缺陷,而直接检测蛋白缺陷的方法复杂且难以实施。在本研究中,我们研究了临床诊断为 HS 的患者中与 HS 相关的遗传变异模式。
使用 Illumina HiSeq 平台对 43 个基因(17 个 RBC 膜蛋白编码基因、20 个 RBC 酶编码基因和 6 个用于鉴别诊断的其他基因)进行多基因靶向测序。
在 59 名 HS 患者中,有 50 名(84.7%)患者在 RBC 膜蛋白编码基因中存在一个或多个显著变异。在六个 RBC 膜蛋白编码基因中检测到 54 个显著变异,包括 46 个新突变,其中 SPTB 变异数量最多(n=28),其次是 ANK1(n=19)、SLC4A1(n=3)、SPTA1(n=2)、EPB41(n=1)和 EPB42(n=1)。同时在三个患者中检测到编码 RBC 酶的基因(ALDOB、GAPDH 和 GSR)的突变。24 名患者(40.7%)存在 UGT1A1 突变。携带 HS 相关基因突变的患者渗透脆性试验的阳性率为 86.8%。
这是第一项针对韩国 HS 患者的大规模遗传研究。我们证明,多基因靶向测序具有较高的敏感性和可行性,可作为诊断 HS 的有力工具。鉴于 HS 的临床和分子诊断存在差异,我们的研究结果表明,需要进行分子遗传学分析以准确诊断 HS。